Selective optimization of side activities: the SOSA approach

被引:97
作者
Wermuth, CG [1 ]
机构
[1] Prestwick Chem, F-67400 Illkirch Graffenstaden, France
关键词
D O I
10.1016/S1359-6446(05)03686-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Selective optimization of side activities of drug molecules (the SOSA approach) is an intelligent and potentially more efficient strategy than HTS for the generation of new biological activities. Only a limited number of highly diverse drug molecules are screened, for which bioavailability and toxicity studies have already been performed and efficacy in humans has been confirmed. Once the screening has generated a hit it will be used as the starting point for a drug discovery program. Using traditional medicinal chemistry as well as parallel synthesis, the initial 'side activity' is transformed into the 'main activity' and, conversely, the initial 'main activity' is significantly reduced or abolished. This strategy has a high probability of yielding safe, bioavailable, original and patentable analogues.
引用
收藏
页码:160 / 164
页数:5
相关论文
共 45 条
[1]   Discovering transthyretin amyloid fibril inhibitors by limited screening [J].
Baures, PW ;
Peterson, SA ;
Kelly, JW .
BIOORGANIC & MEDICINAL CHEMISTRY, 1998, 6 (08) :1389-1401
[2]   Absorption classification of oral drugs based on molecular surface properties [J].
Bergström, CAS ;
Strafford, M ;
Lazorova, L ;
Avdeef, A ;
Luthman, K ;
Artursson, P .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (04) :558-570
[3]  
BIZIERE K, 1982, ARZNEIMITTEL-FORSCH, V32-2, P824
[4]   Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6,7,1-hi]indoles:: Discovery of potent, selective phosphodiesterase type 4 inhibitors [J].
Burnouf, C ;
Auclair, E ;
Avenel, N ;
Bertin, B ;
Bigot, C ;
Calvet, A ;
Chan, K ;
Durand, C ;
Fasquelle, V ;
Féru, F ;
Gilbertsen, R ;
Jacobelli, H ;
Kebsi, A ;
Lallier, E ;
Maignel, J ;
Martin, B ;
Milano, S ;
Ouagued, M ;
Pascal, Y ;
Pruniaux, MP ;
Puaud, J ;
Rocher, MN ;
Terrasse, C ;
Wrigglesworth, R ;
Doherty, AM .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (25) :4850-4867
[5]   Aminopyridazines as acetylcholinesterase inhibitors [J].
Contreras, JM ;
Rival, YM ;
Chayer, S ;
Bourguignon, JJ ;
Wermuth, CG .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (04) :730-741
[6]   Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors [J].
Contreras, JM ;
Parrot, I ;
Sippl, W ;
Rival, YM ;
Wermuth, CG .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (17) :2707-2718
[7]   THE BIOTRANSFORMATION OF [C-14] MINAPRINE IN MAN AND 5 ANIMAL SPECIES [J].
DAVI, H ;
DUPONT, P ;
JEANNIOT, JP ;
RONCUCCI, R ;
CAUTREELS, W .
XENOBIOTICA, 1981, 11 (11) :735-747
[8]   Discovering drugs through biological transformation: Role of pharmacologically active metabolites in drug discovery [J].
Fura, A ;
Shu, YZ ;
Zhu, MS ;
Hanson, RL ;
Roongta, V ;
Humphreys, WG .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (18) :4339-4351
[9]   NEUROCHEMICAL EFFECTS OF MINAPRINE, A NOVEL PSYCHOTROPIC-DRUG, ON THE CENTRAL CHOLINERGIC SYSTEM OF THE RAT [J].
GARATTINI, S ;
FORLONI, GL ;
TIRELLI, S ;
LADINSKY, H ;
CONSOLO, S .
PSYCHOPHARMACOLOGY, 1984, 82 (03) :210-214
[10]   IKs channel blockers:: potential antiarrhythmic agents [J].
Gerlach, U .
DRUGS OF THE FUTURE, 2001, 26 (05) :473-484